Iproteos is developing a drug to treat the symptoms of schizophrenia and has already obtained its first results in animals.
The company has completed a first funding round, achieving more than 100,000 euros, and anticipates a second round of funding from business angels this autumn.
Set up in 2011 as a biotech spin-off from the Institute for Research in Biomedicine and the University of Barcelona, Iproteos has received support from the Ministry of Enterprise and Labour through the Evaluation Units managed by ACC1Ó.
Researchers headed by Maria Macias an ICREA researcher at the Institute for Research in Biomedicine (IRB Barcelona) and Joan Massagué, a Howard Hughes Medical Institute investigator at Memorial Sloan-Kettering Cancer Center (MSKCC) in New York, have identified a new molecular mechanism that plays a crucial role in the control of the activation of certain genes associated with cancer.
Through detailed structural and biochemical studies, the researchers identified a key domain present in a family of proteins called Smads, whose binding determines whether the transcription of genes controlled by the TGF-beta and BMP signaling cascades will be bound by activators or labeled for...
The Nek9 protein is required for chromosomes to separate into two identical groups.
Nek9 exerts its action between two molecules of interest for the pharmaceutical industry as anti-tumoral agents, and for which inhibitors are already in advanced stages of clinical trials. Nek9 could be added to the list of candidates.
The objective is to further our understanding of why beta cells, responsible for the production of insulin, become insensitive to insulin.
"la Caixa" International PhD Programme celebrates its fourth edition with 40 new fellowships generously funded by the Social Programme of this savings bank foundation.
Next September, IRB Barcelona will welcome 10 new students within this programme. With them, the institute will be hosting 50 "la Caixa" PhD students.
Yesterday, 17 July, the Catalan Government announced the award of the Narcís Monturiol Plaque to the Institute for Research in Biomedicine (IRB Barcelona).
First given by the Catalan Government in 1982, these awards recognize the contribution of Catalan organisations to furthering science and technology. The “Obra Social “LaCaixa”” and the “Fundació Fero” are the other two organisations presented the award this year. The presentation ceremony will be held in October in the “Palau de la Generalitat”.
The Government also announced the awards of Narcís Monturiol Medals to thirteen authorities in the fields of science and technology: Salvador Barberà, Joaquim...
Founded in 2010, the biotech company Inbiomotion is specialized in the development of markers for the prediction of bone metastases from the analysis of the primary tumor.
Ysios capital, a venture capital firm focused on biomedicine, heads the funding round, which also involves the Fundació Vila Casas and JVRisk Technologies. This operation, the ninth since the start up of Ysios, is also the first made by this company in a spin-off from a public, basic research centre.
The increase in share capital is aimed at promoting the development of diagnostic tools for metastasis based on technology that the company licensed from IRB Barcelona and ICREA.
In the framework of the XVI National Call for Scientific and Technical Research Funding 2011, in the Life Sciences Section.
"La Festa de la Ciència i la Tecnologia" take place this weekend, June 16-17, in Barcelona's Parc de la Ciutadella
Different kinds of tumors start to develop as a result of specific combinations of errors in the processes that safeguard cell integrity.